What Is PF-4618433?

PF-4618433 is a potent, selective inhibitor of ubiquitin-specific protease 7 (USP7), a cysteine deubiquitinase enzyme that plays a central role in the ubiquitin–proteasome system. By removing ubiquitin chains from target substrates, USP7 regulates the stability of multiple oncologically relevant proteins, most notably MDM2 and its primary substrate, the tumor suppressor p53.

As a small-molecule chemical probe, PF-4618433 has been employed in cell-based and biochemical assays to dissect the functional consequences of USP7 inhibition, providing mechanistic insight into how deubiquitinase activity controls cell fate decisions in cancer cells.

Mechanism of Action

USP7 deubiquitinates MDM2, thereby stabilizing MDM2 protein and promoting MDM2-mediated ubiquitination and proteasomal degradation of p53. In this way, USP7 functions as a negative regulator of the p53 tumor suppressor pathway. Inhibition of USP7 by PF-4618433 disrupts this regulatory cycle, leading to reduced MDM2 stability, accumulation of p53, and induction of p53-dependent transcriptional programs including apoptosis and cell-cycle arrest.

PF-4618433 achieves selectivity for USP7 within the broader deubiquitinase enzyme family through its specific binding to the catalytic domain of USP7, blocking substrate access and enzymatic activity. Researchers utilize this compound to validate USP7 as a therapeutic target and to understand the biological consequences of acute pharmacological inhibition compared to genetic knockdown approaches.

Applications in Research

PF-4618433 is used across a range of experimental contexts in cancer biology and chemical biology research:

• Biochemical enzyme assays: Measuring IC₅₀ values and characterizing inhibitor kinetics against recombinant USP7.
• Cell viability and apoptosis assays: Evaluating the anti-proliferative effects of USP7 inhibition in tumor cell lines, particularly those retaining wild-type p53.
• Western blotting and immunoprecipitation: Monitoring changes in MDM2 and p53 protein levels following compound treatment as pharmacodynamic readouts.
• Combination studies: Investigating synergy between USP7 inhibitors and other targeted agents, including MDM2 antagonists or DNA-damaging chemotherapeutics.
• Target validation: Confirming on-target cellular effects and comparing outcomes to USP7 siRNA or CRISPR knockdown models.

Handling, Formulation and Storage Recommendations

Proper handling of PF-4618433 is essential to ensure experimental reproducibility and compound integrity. The following general guidelines apply; always consult the official product datasheet (SKU: P651173) for compound-specific parameters:

• Solubility: PF-4618433 is typically soluble in dimethyl sulfoxide (DMSO). Prepare stock solutions at a concentration that allows dilution to ≤0.1% DMSO in final assay media to minimize solvent cytotoxicity artifacts.
• Storage: Store lyophilized or powdered compound at −20 °C in a desiccated environment, protected from light and moisture. Avoid repeated freeze–thaw cycles of stock solutions.
• Stability: Confirm solution stability according to the datasheet prior to long-term storage of prepared stocks.
• Safety: Handle as a potent bioactive compound using standard laboratory PPE. Refer to the Safety Data Sheet (SDS) for hazard classification and disposal guidance.